Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
February 15 2024 - 7:30AM
Business Wire
- Collaboration combines Intellia’s leading CRISPR-based
platform, including its DNA writing technology, with ReCode’s
proprietary Selective Organ Targeting (SORT) lipid nanoparticle
(LNP) to extend the reach of gene editing to disease-causing
targets in the lung
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading
clinical-stage gene editing company focused on revolutionizing
medicine with CRISPR-based therapies, and ReCode Therapeutics, a
clinical-stage genetic medicines company using tissue-specific
delivery to power the next wave of mRNA and gene correction
therapeutics, today announced a strategic collaboration to develop
novel genomic medicines for the treatment of cystic fibrosis (CF).
CF is a genetic disease caused by mutations in the CFTR gene,
leading to the accumulation of thick mucus in the lungs, digestive
systems and other organs. CF can result in life-threatening
infections, respiratory failure and other serious
complications.
The collaboration will leverage Intellia’s proprietary
CRISPR-based gene editing platform, including its DNA writing
technology, and ReCode’s proprietary Selective Organ Targeting
(SORT) lipid nanoparticle (LNP) delivery platform to precisely
correct one or more CF disease-causing gene mutations. As part of
the agreement, the companies will focus initial research efforts on
therapeutic approaches that address CF for patients who have
limited or no treatment options available, with the opportunity to
expand the scope of the collaboration in later phases. Intellia
will be responsible for the design of the editing strategy and
research-grade components for the investigational therapies. ReCode
will lead the subsequent preclinical and clinical development.
ReCode will also lead worldwide commercialization for certain
programs arising from the collaboration. Intellia will be eligible
to receive pre-specified development and commercial milestone
payments, as well as royalties on potential sales. Intellia may
also exercise an option to lead commercialization in the U.S. for
certain programs.
“Intellia’s vision to realize the full promise of gene editing
includes extending the reach of our industry-leading CRISPR-based
platform to targets outside the liver. This collaboration with
ReCode is aimed at achieving that goal as we work together to
accelerate the development of potentially life-changing therapies
for people with cystic fibrosis,” said Intellia President and Chief
Executive Officer John Leonard, M.D. “Building on our CRISPR/Cas9
capabilities, we have made important progress advancing our
proprietary DNA writing technology to enable a range of precise
editing strategies. We are excited to combine our gene editing
expertise and platform with ReCode’s novel lung-directed LNP
delivery platform.”
“We are excited to partner with Intellia, a clear leader in the
gene editing space, with the ultimate goal of bringing
life-altering therapies to CF patients,” said ReCode Chief
Executive Officer Shehnaaz Suliman, M.D. (MB ChB), M.B.A., M.Phil.
“This collaboration provides further validation of ReCode's SORT
LNP platform to deliver diverse gene editing modalities to specific
cells and tissues. By combining our highly synergistic technologies
and capabilities, we are excited about the potential to enable a
faster path for next-generation gene editing therapeutics to CF
patients.”
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading
clinical-stage gene editing company focused on revolutionizing
medicine with CRISPR-based therapies. The company’s in vivo
programs use CRISPR to enable precise editing of disease-causing
genes directly inside the human body. Intellia’s ex vivo programs
use CRISPR to engineer human cells outside the body for the
treatment of cancer and autoimmune diseases. Intellia’s deep
scientific, technical and clinical development experience, along
with its people, is helping set the standard for a new class of
medicine. To harness the full potential of gene editing, Intellia
continues to expand the capabilities of its CRISPR-based platform
with novel editing and delivery technologies. Learn more at
intelliatx.com and follow us @intelliatx.
About ReCode Therapeutics
ReCode Therapeutics is a clinical-stage genetic medicines
company using precision delivery to power the next wave of mRNA and
gene correction therapeutics. ReCode’s proprietary Selective Organ
Targeting (SORT) lipid nanoparticle (LNP) platform enables highly
precise and targeted delivery of genetic medicines directly to the
organs, tissues and cells implicated in disease, enabling improved
efficacy and potency. ReCode’s lead programs include RCT1100 for
the treatment of primary ciliary dyskinesia caused by pathogenic
mutations in the DNAI1 gene, and RCT2100 for the treatment of the
10-13% of cystic fibrosis patients who have Class I mutations in
the CFTR gene and do not respond to currently approved CFTR
modulators. RCT1100 and RCT2100 are inhaled disease-modifying
mRNA-based therapies formulated using the SORT LNP delivery
platform. ReCode is expanding its pipeline to develop potential
therapies for other rare and common genetic diseases, including
musculoskeletal, central nervous system, liver and infectious
disease indications.
ReCode has been recognized by the San Francisco Business Times
and Silicon Valley Business Journal as a Best Place to Work. For
more information, visit www.recodetx.com and follow us on
LinkedIn.
Intellia Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, express or implied
statements regarding Intellia’s beliefs and expectations regarding:
its strategy, business plans and focus; its ability to leverage its
proprietary CRISPR-based gene editing platform, including its DNA
writing technology, and to combine its platform with the
proprietary lipid nanoparticle (“LNP”) delivery platform developed
by ReCode Therapeutics, Inc. (“ReCode”) to precisely correct one or
more cystic fibrosis (“CF”) disease-causing gene mutations; its
ability to develop therapeutic approaches that address CF for
patients who have limited or no treatment options available, and to
expand the scope of the collaboration in later phases; its ability
to commercialize in the U.S. the products that may result from its
collaboration with ReCode; and the expected strategic benefits of
any current or future collaborations, including its collaboration
with ReCode.
Any forward-looking statements in this press release are based
on management's current expectations and beliefs of future events,
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks related to Intellia’s ability to protect and
maintain its intellectual property portfolio; risks related to
Intellia’s relationship with third parties, including its licensors
and licensees; risks related to the ability of Intellia’s licensors
to protect and maintain their intellectual property position;
uncertainties related to the development of the company’s product
candidates, including product candidates to be developed in its
collaboration with ReCode, and the authorization, initiation and
conduct of studies and other development requirements for such
product candidates; the risk that any one or more of Intellia’s or
its collaborators’ product candidates (including the product
candidates to be developed with ReCode) will not be successfully
developed and commercialized; the risk that the results of
preclinical studies or clinical studies will not be predictive of
future results in connection with future studies; and the risk that
Intellia’s collaboration with ReCode or its other collaborations
will not continue or will not be successful. These and other risks
and uncertainties are described in greater detail in Intellia’s
other filings with the Securities and Exchange Commission,
including the section entitled “Risk Factors” in Intellia’s most
recent annual report on Form 10-K and quarterly report on Form
10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in other filings. Any forward-looking
statements contained in this press release represent Intellia’s
views only as of the date hereof and should not be relied upon as
representing its views as of any subsequent date. Intellia
explicitly disclaims any obligation to update any forward-looking
statements, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240215392146/en/
Intellia Contacts:
Investors:
Ian Karp Senior Vice President, Investor Relations and Corporate
Communications ian.karp@intelliatx.com
Lina Li Senior Director, Investor Relations and Corporate
Communications lina.li@intelliatx.com
Media:
Matt Crenson Ten Bridge Communications media@intelliatx.com
TBCIntellia@tenbridgecommunications.com
ReCode Contacts:
Investors:
Anne Marie Fields Stern IR AnneMarie.Fields@sternir.com
IR@recodetx.com
Media:
Erica Jefferson Senior Vice President, Corporate Affairs
ejefferson@recodetx.com
Tara Cooper The Grace Group tara@gracegroup.us
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024